After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

A Boston-based nonprofit is among six organizations that on Monday filed a lawsuit against the U.S. Health and Human Services ...

The decision to cancel the Moderna contracts, undoubtedly driven by anti-vaccine crusader and HHS Secretary Robert F. Kennedy, Jr., puts the entire nation at risk, as does this administration’s ...